CAJ | 학술논문

目的：评价吡柔比星与吉西他滨膀胱内灌注预防膀胱癌术后复发的疗效。方法：将42例保留膀胱手术治疗的膀胱癌患者分为A、B组，A组24例，B组18例。分别使用吡柔比星与吉西他滨进行预防灌注，全部患者均术后即刻膀胱内灌注化疗，每周1次，共6次；以后每月1次直至1~2年，并做随访和疗效比较。结果：A、B两组生存率均为100％；A组复发率为25％（6/24），B组复发率为27.8％（5/18），两组患者2年生存率、复发率比较差异无显著性意义（ P>0.05）。A组和B组用药后膀胱刺激症状发生率、尿道狭窄发生率、全身不良反应发生率比较差异无显著性意义（ P>0.05）。结论：吡柔比星与吉西他滨均可降低膀胱癌术后复发的机率，两者疗效无明显差异。膀胱内灌注预防浅表性膀胱癌术后复发近期疗效满意，副作用较轻，耐受性良好。
목적：평개필유비성여길서타빈방광내관주예방방광암술후복발적료효。방법：장42례보류방광수술치료적방광암환자분위A、B조，A조24례，B조18례。분별사용필유비성여길서타빈진행예방관주，전부환자균술후즉각방광내관주화료，매주1차，공6차；이후매월1차직지1~2년，병주수방화료효비교。결과：A、B량조생존솔균위100％；A조복발솔위25％（6/24），B조복발솔위27.8％（5/18），량조환자2년생존솔、복발솔비교차이무현저성의의（ P>0.05）。A조화B조용약후방광자격증상발생솔、뇨도협착발생솔、전신불량반응발생솔비교차이무현저성의의（ P>0.05）。결론：필유비성여길서타빈균가강저방광암술후복발적궤솔，량자료효무명현차이。방광내관주예방천표성방광암술후복발근기료효만의，부작용교경，내수성량호。
Objective:To evaluate the effect of prevention of postoperative recurrence of bladder cancer with intra-vesical between pirarubicin and gemcitabine. Methods:All 42 patients treated with bladder preservation surgery with bladder cancer were divided into A,B group. A group 24 cases,B group 1 8 cases . Respectively prevention infusionwith pirarubicin and gemcitabine. All patients were started one week after intravesical chemotherapy once a week for a total of six times,once a month until after 1 ~2 years,and follow-up. Results:In A,B groups survival rates were 100%,recurrence rate was 25% in group A,27. 8% in group B,2-year survival rate,the recurrence rate difference was not statistically significant. The difference of the incidence of bladder irritation,urethral stricture incidence and systemic adverse reaction rate was not statistically significant. Conclusion:Pirarubicin and gemcitabine can reduce the chances of recurrence of bladder cancer,there is no significant difference in efficacy. Intravesical prophylaxis of super-ficial bladder cancer recurrence recent results were satisfactory,with less serious side effects.